Laidlaw was bookrunning manager, Feltl was the co-manager for offer
By Devika Patel
Knoxville, Tenn., May 29 – Viking Therapeutics, Inc. said the underwriters for its initial public offering of stock opted to exercise the deal’s $3.6 million greenshoe in full, lifting total proceeds of the offering to $27.6 million. The deal was announced July 1, 2014 and priced for $24 million with the greenshoe on April 29.
The company sold 3.45 million common shares at $8.00 apiece. Of the shares, 450,000 were part of the fully exercised greenshoe.
Laidlaw & Co. (UK) Ltd. was the bookrunning manager.
Proceeds will be used for clinical development, working capital and other general corporate purposes.
The biopharmaceutical company is based in San Diego. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “VKTX.”
| Issuer: | Viking Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $27.6 million, including $3.6 million greenshoe of 450,000 shares
|
| Shares: | 3.45 million
|
| Price: | $8.00
|
| Warrants: | No
|
| Bookrunner: | Laidlaw & Co. (UK) Ltd.
|
| Co-manager: | Feltl and Co., Inc.
|
| Announcement date: | July 1, 2014
|
| Pricing date: | April 29
|
| Settlement date: | May 29
|
| Stock exchange: | Nasdaq: VKTX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
